COCP Cocrystal Pharma Inc
Price (delayed)
$1.76
Market cap
$17.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.77
Enterprise value
$1.44M
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses.
Highlights
The debt has contracted by 2.3% from the previous quarter
Cocrystal Pharma's EPS has increased by 23% YoY but it has decreased by 7% from the previous quarter
Cocrystal Pharma's net income has increased by 8% YoY but it has decreased by 7% from the previous quarter
The company's quick ratio has shrunk by 66% YoY and by 25% QoQ
The company's equity fell by 50% YoY and by 23% QoQ
Key stats
What are the main financial stats of COCP
Market
Valuations
Earnings
Shares outstanding
10.17M
Market cap
$17.91M
Enterprise value
$1.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$17.21M
EBITDA
-$17.16M
Free cash flow
-$14.28M
Per share
Balance sheet
Liquidity
EPS
-$1.77
Free cash flow per share
-$1.4
Book value per share
$1.71
Revenue per share
$0
TBVPS
$2.12
Total assets
$21.57M
Total liabilities
$4.18M
Debt
$1.78M
Equity
$17.39M
Working capital
$17.01M
Debt to equity
0.1
Current ratio
7.41
Quick ratio
6.88
Net debt/EBITDA
0.96
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-64%
Return on equity
-73.9%
Return on invested capital
-637.2%
Return on capital employed
-91%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COCP stock price
How has the Cocrystal Pharma stock price performed over time
Intraday
1.73%
1 week
2.92%
1 month
-3.3%
1 year
-11.11%
YTD
2.33%
QTD
-24.46%
Financial performance
How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.72M
Net income
-$17.93M
Gross margin
N/A
Net margin
N/A
Cocrystal Pharma's net income has increased by 8% YoY but it has decreased by 7% from the previous quarter
The operating income has contracted by 6% from the previous quarter but it has grown by 4.7% YoY
Growth
What is Cocrystal Pharma's growth rate over time
Valuation
What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
1.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cocrystal Pharma's EPS has increased by 23% YoY but it has decreased by 7% from the previous quarter
The company's equity fell by 50% YoY and by 23% QoQ
The stock's P/B is 29% above its last 4 quarters average of 0.8 and 3% above its 5-year quarterly average of 1.0
Efficiency
How efficient is Cocrystal Pharma business performance
Cocrystal Pharma's ROE has decreased by 44% YoY and by 26% from the previous quarter
COCP's return on invested capital is up by 35% year-on-year but it is down by 6% since the previous quarter
The ROA has contracted by 31% YoY and by 21% from the previous quarter
Dividends
What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COCP.
Financial health
How did Cocrystal Pharma financials performed over time
The company's total liabilities has surged by 162% YoY and by 6% QoQ
The company's current ratio has shrunk by 67% YoY and by 28% QoQ
The debt is 90% less than the equity
The company's equity fell by 50% YoY and by 23% QoQ
COCP's debt to equity is up by 25% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.